felin
infecti
periton
fip
welldocu
infecti
diseas
cat
especi
kitten
adolesc
young
adult
shelter
kitten
fosterrescu
catteri
pedersen
caus
fip
viru
fipv
posit
singl
strand
rna
viru
belong
famili
coronavirida
speci
alphacoronaviru
subspeci
felin
coronaviru
biotyp
fip
viru
fipv
teke
thiel
fipv
infect
complex
immunopathogenesi
featur
share
coronaviru
infect
de
wild
et
al
becom
one
research
infecti
diseas
cat
sinc
discoveri
half
centuri
ago
kipar
meli
pedersen
pedersen
teke
thiel
despit
advanc
modern
treatment
option
fip
remain
palli
vaccin
proven
either
unsaf
ineffect
pedersen
emerg
sarsassoci
coronaviru
provid
impetu
invest
antivir
discoveri
focus
coronavirus
de
clercq
proteas
inhibitor
first
demonstr
highli
effect
experiment
fipv
infect
kim
et
al
subsequ
studi
cat
natur
acquir
fip
show
much
difficult
treat
pedersen
et
al
nevertheless
first
studi
demonstr
potenti
antivir
compound
treat
fip
natur
cat
remain
diseas
free
well
one
year
week
treatment
pedersen
et
al
adenin
cnucleosid
ribos
analogu
fig
small
molecul
exhibit
potent
antivir
activ
number
rna
virus
includ
zoonot
sever
acut
respiratori
syndrom
sar
coronaviru
cho
et
al
phosphoramid
prodrug
previous
shown
inhibit
replic
sever
taxonom
divers
rna
virus
middl
east
respiratori
syndrom
viru
ebola
viru
lassa
fever
viru
junin
viru
respiratori
syncyti
viru
low
cytotox
widerang
cell
line
sheahan
et
al
also
shown
protect
rhesu
monkey
experiment
ebola
viru
infect
warren
et
al
requir
intracellular
phosphoryl
via
cellular
kinas
nucleosid
monophosph
subsequ
activ
triphosph
metabolit
ntp
cho
et
al
sheahan
et
al
warren
et
al
fig
activ
ntp
analog
function
competitor
natur
nucleosid
triphosph
viral
rna
synthesi
activ
form
shown
inhibit
rsv
rnadepend
rna
polymeras
mediat
transcript
incorpor
nascent
viral
transcript
caus
prematur
termin
sheahan
et
al
hypothes
would
activ
felin
cell
attenu
fipv
replic
low
cytotox
felin
cell
vitro
effect
treat
cat
experiment
induc
fip
specif
pathogen
free
spf
cat
purpos
bred
felin
research
laboratori
frl
breed
coloni
felin
nutrit
center
uc
davi
twelv
adolesc
cat
use
experiment
infect
six
young
adult
cat
pharmacokinet
studi
cat
experi
hous
open
room
facil
frl
care
frl
staff
anim
caretak
experi
involv
use
laboratori
bred
cat
conduct
uc
davi
iacuc
protocol
uc
davi
polici
care
use
anim
teach
research
requir
univers
practic
procur
hous
care
use
anim
must
conform
ilar
guid
care
use
laboratori
anim
guid
care
use
agricultur
anim
research
teach
regul
unit
state
depart
agricultur
usda
issu
usda
implement
anim
welfar
act
awa
amend
cfr
chapter
public
health
servic
polici
human
care
use
laboratori
anim
addit
univers
polici
requir
facil
anim
hous
program
associ
facil
must
accredit
associ
assess
accredit
laboratori
anim
care
aaalac
intern
crandellre
felin
kidney
crfk
cell
propag
ml
flask
ml
fb
infect
confluenc
ml
cellcultur
supernat
contain
tissu
cultur
infecti
per
ml
serotyp
ii
fipv
genbank
incub
h
flask
frozen
min
thaw
mixtur
cell
origin
cultur
fluid
centrifug
remov
cellular
subcellular
debri
supernat
store
liquid
nitrogen
level
infecti
viru
aliquot
cultur
supernat
determin
crfk
cell
grown
describ
well
plate
infect
one
mlwell
serial
dilut
frozen
supernat
plate
incub
h
stain
crystal
violet
fig
well
score
cpe
calcul
six
replic
reedmuench
method
viral
rna
isol
cultur
supernat
qiaamp
viral
rna
mini
kit
qiagen
pellet
cell
rnaeasi
qiagen
accord
manufactur
instruct
dnase
treatment
isol
rna
accomplish
turbo
dnase
ambion
rna
revers
transcrib
cdna
origen
firststrand
cdna
synthesi
system
qrtpcr
origen
control
reaction
exclud
revers
transcriptas
includ
sampl
fipv
rna
copi
number
measur
qrtpcr
previous
describ
murphi
et
al
pcr
primer
base
consensu
sequenc
felin
coronaviru
gene
sequenc
forward
primer
agt
tta
gat
ttg
att
tgg
caa
tgc
tag
sequenc
revers
primer
aat
cac
tag
atc
cag
acg
tta
gct
control
reaction
exclud
cdna
water
templat
includ
assay
realtim
pcr
gapdh
housekeep
gene
gapdh
perform
parallel
result
normal
per
copi
gapdh
quantif
fipv
rna
copi
number
base
standard
curv
gener
viral
transcript
prepar
vitro
transcript
plasmid
invitrogen
contain
nucleotidelong
amplicon
provid
gilead
scienc
inc
infect
cell
treat
um
row
um
row
b
um
row
c
um
row
um
row
e
um
row
f
um
row
g
untreat
uninfect
cell
row
h
c
nonlinear
regress
analysi
util
data
determin
um
protein
sampl
plasma
aqueou
humor
cerebrospin
fluid
csf
precipit
ad
acetonitril
final
concentr
presenc
intern
standard
nm
indol
sampl
filter
remov
precipit
protein
dri
complet
stream
nitrogen
reconstitut
formic
acid
acetonitril
lcmsm
analysi
concentr
frozen
sampl
cultur
cell
pbmc
use
triphosph
analysi
resuspend
ml
methanol
contain
intern
standard
nm
least
min
result
supernat
dri
centrifug
evapor
genevac
stone
ridg
ny
sampl
reconstitut
aqueou
solut
mm
ammonium
phosphat
ph
analyt
separ
use
x
mm
u
luna
hst
column
phenomenex
torranc
ca
connect
shimadzu
columbia
md
ternari
pump
system
ht
pal
autosampl
leap
technolog
carrboro
nc
multistag
linear
gradient
acetonitril
mobil
phase
contain
mm
ammonium
format
ph
mm
dimethylhexylamin
flow
rate
u
lmin
use
separ
analyt
detect
perform
api
appli
biosystem
foster
citi
ca
msm
oper
posit
ion
multipl
reaction
monitor
mode
analyt
quantifi
use
standard
curv
rang
concentr
pm
prepar
extract
untreat
cell
cytotox
assess
use
commerci
avail
procedur
celltox
green
cytotox
assay
promega
cytotox
quantifi
intens
fluoresc
dye
select
bind
dna
apoptoticnecrot
cell
fluoresc
crfk
cell
well
plate
treat
um
concentr
compar
untreat
crfk
cell
neg
control
cell
treat
cell
lyse
reagent
provid
manufactur
posit
control
inhibit
viru
replic
either
crfk
cell
natur
infect
periton
macrophag
quantit
visual
colorimetr
inhibit
cpe
well
suppress
viral
rna
express
qrtpcr
visual
method
crfk
cell
grown
well
tissu
cultur
plate
contain
ul
fb
cellswel
cell
infect
confluenc
gentli
rock
min
ad
concentr
rang
um
unattach
cell
remov
gentl
wash
h
attach
cell
fix
methanol
stain
crystal
violet
cytopath
effect
measur
visual
fig
use
plate
scanner
intens
crystal
violet
stain
tissu
cultur
well
infect
viru
alon
posit
control
uninfect
well
neg
control
run
parallel
crfk
cell
inhibit
viral
rna
assay
cultur
six
well
plate
infect
h
fipv
describ
treat
um
cultur
h
adher
cell
gentli
detach
cell
scraper
exist
medium
cultur
supernat
freezethaw
test
qrtpcr
assay
perform
six
well
replic
concentr
inhibit
infect
determin
nonlinear
regress
analysi
prism
graphpad
abil
inhibit
replic
wild
type
strain
fipv
natur
host
cell
determin
ex
vivo
manner
use
qrtpcr
ten
ml
ascit
fluid
obtain
abdominocentesi
two
client
own
cat
natur
acquir
effus
fip
enrol
separ
studi
pedersen
et
al
fluid
dilut
fb
aliquot
two
tissu
cultur
flask
volum
mlflask
cultur
maintain
h
allow
peritonealtyp
macrophag
attach
flask
neutrophil
lymphocyt
remain
free
medium
medium
detach
cell
replac
cultur
maintain
addit
h
adher
cell
gentli
remov
cell
scraper
medium
cell
freezethaw
twice
aliquot
frozen
pharmacokinet
pk
studi
perform
laboratori
cat
determin
metabol
acut
anim
toxic
dissolv
concentr
mgml
ethanol
propylen
glycol
peg
water
adjust
ph
concentr
hcl
six
laboratori
cat
randomli
divid
group
n
iv
administr
b
n
sc
administr
time
point
zero
group
cat
administ
mg
compoundkg
bodi
weight
intraven
group
b
cat
receiv
mg
compoundkg
subcutan
cat
monitor
sign
acut
toxic
elev
puls
respiratori
distress
cyanosi
diarrhea
anorexia
drool
vomit
ataxia
weight
loss
chang
rectal
temperatur
daili
five
day
serial
ml
whole
blood
sampl
edta
obtain
later
saphen
superfici
brachial
jugular
venipunctur
cat
h
collect
blood
sampl
immedi
place
ice
centrifug
rpm
min
isol
plasma
pipet
ml
microcentrifug
tube
frozen
analysi
free
buffi
coat
fraction
blood
collect
suspend
ml
phosphat
free
trisbuff
salin
tb
mm
triscl
ph
mm
nacl
pbmc
isol
ficol
hypaqu
densiti
gradient
centrifug
plasma
pbmc
fraction
snap
frozen
liquid
nitrogen
ship
dri
ice
gilead
scienc
inc
foster
citi
ca
analys
plasma
drug
concentr
intracellular
phosphoryl
analys
twelv
six
ninemonthold
spf
cat
experiment
infect
intraperiton
rout
catpassag
serotyp
strain
origin
catpassag
histori
prepar
infecti
inoculum
method
challengeexposur
monitor
diseas
sign
respons
treatment
use
isol
previous
report
kim
et
al
pedersen
et
al
nontreat
control
infect
cat
includ
base
human
reason
histor
data
outcom
ident
challengeexposur
pedersen
et
al
fever
absolut
lymphopenia
inappet
jaundic
abdomin
effus
appear
week
infect
around
cat
rapidli
increas
sever
next
one
two
week
would
prove
fatal
intervent
taken
kim
et
al
pedersen
et
al
cat
treat
day
either
mgkg
group
n
mgkg
group
b
n
two
week
diseas
cours
becam
appar
usual
within
three
day
cat
treat
fluid
replac
l
lactat
ringer
solut
sc
h
meloxicam
mgkg
po
h
interven
period
prevent
undu
suffer
ancillari
treatment
stop
treatment
instig
cat
recurr
diseas
sign
usual
within
four
week
initi
treatment
treat
regimen
two
addit
week
cat
observ
minimum
month
recurr
fip
data
present
mean
three
valu
standard
deviat
display
error
bar
analysi
varianc
perform
anova
data
set
global
differ
identifi
tukeykram
multipl
comparison
test
util
pairwis
comparison
mean
respons
treatment
group
nonlinear
regress
analysi
perform
dose
respons
data
statist
perform
prism
graphpad
softwar
inc
la
jolla
ca
probabl
valu
deem
statist
signific
determin
toxic
crfk
cell
prerequisit
studi
make
determin
crfk
cell
treat
um
h
cell
appear
grew
normal
concentr
fail
uptak
fluoresc
dye
celltox
green
h
data
shown
cytotox
therefor
um
cytotox
cpe
observ
crfk
cell
expos
um
longer
period
h
either
visual
quantit
crystal
violet
stain
crucial
show
inhibit
fipv
replic
cultur
cell
low
concentr
done
initi
infect
crfk
cell
monolay
serotyp
ii
treat
concentr
rang
none
um
one
hour
later
crfk
cell
protect
virusinduc
cpe
dosedepend
manner
test
h
later
crystal
violet
stain
fig
experi
repeat
three
time
similar
result
effect
calcul
um
fig
inhibit
fipv
replic
also
measur
qrtrcr
crfk
cell
infect
expos
one
hour
later
um
h
fig
complet
inhibit
viral
rna
express
seen
um
partial
inhibit
um
inhibit
lower
concentr
p
fig
serotyp
strain
adapt
vitro
grow
fibroblast
type
cell
line
comparison
fipv
isol
natur
serotyp
specif
tropism
peritonealtyp
macrophag
inhibit
replic
crfk
cell
may
parallel
natur
condit
discount
possibl
ex
vivo
infect
periton
macrophag
cultur
establish
ascit
two
unrel
cat
naturallyacquir
effus
fip
ex
vivo
cultur
first
cat
treat
um
h
result
signific
reduct
cellassoci
fipv
rna
transcript
approxim
rel
untreat
cell
fig
experi
repeat
ascit
cell
isol
second
cat
naturallyacquir
fip
incub
extend
h
cultur
also
demonstr
signific
p
reduct
cellassoci
fipv
rna
rel
untreat
cell
data
shown
sustain
three
day
crfk
cell
expos
um
import
demonstr
intern
felin
cell
phosphoryl
within
cell
activ
form
proand
activateddrug
level
sustain
intracellular
level
nonphosphoryl
crfk
cell
expos
um
prodrug
threeday
period
remain
steadi
pm
million
cell
fig
pharmacolog
activ
triphosph
cultur
also
test
found
hold
steadi
concentr
around
pmmillion
cell
threeday
period
intracellular
volum
typic
cultur
mammalian
cell
averag
fl
pl
bryan
et
al
would
make
intracellular
triphosph
level
singl
cell
um
near
calcul
crfk
cultur
fig
effect
blood
level
sustain
h
follow
sc
iv
dose
mgkg
high
level
triphosph
achiev
pbmc
essenti
determin
metabol
cat
prior
anim
infect
studi
done
standard
pharmacokinet
pk
studi
two
cat
administ
mg
kg
subcutan
two
cat
receiv
dose
intraven
plasma
cell
pbmc
level
proand
measur
defin
time
overal
plasma
pharmacokinet
profil
similar
subcutan
intraven
group
fig
area
curv
auc
h
valu
um
hl
respect
intracellular
triphosph
concentr
pbmc
appear
higher
cat
administ
sc
rout
differ
signific
due
sampl
variat
number
fig
concentr
triphosph
pbmc
sustain
time
higher
level
prodrug
fig
also
time
higher
calcul
two
differ
method
crfk
cultur
fig
concentr
aqueou
humor
csf
onefifth
plasma
fip
well
known
involv
eye
cn
pedersen
therefor
import
know
well
penetr
bloodbrain
bloodey
barrier
two
young
adult
cat
given
mgkg
sc
two
cat
untreat
provid
control
fluid
sampl
plasma
venou
blood
aqueou
humor
anterior
chamber
centesi
csf
cisterna
magnum
centesi
collect
two
hour
later
prodrug
level
compar
plasma
level
parent
highest
blood
um
lower
ocular
aqueou
humor
plasma
lowest
csf
um
plasma
combin
level
drug
aqueou
humor
csf
averag
blood
plasma
result
prior
cell
cultur
pk
studi
indic
would
effect
treatment
fip
cat
suggest
effect
dosag
regimen
test
experiment
infect
studi
laboratori
cat
inocul
intraperiton
strain
fipv
maintain
near
wildtyp
possibl
well
character
past
studi
kim
et
al
pedersen
et
al
twelv
adolesc
laboratori
cat
challengeexpos
fipv
respons
treatment
monitor
termin
diseas
sign
becam
appar
ten
cat
demonstr
clinic
sign
consist
fip
within
day
two
cat
remain
healthi
fig
clinic
sign
fip
affect
cat
start
hyperthermia
f
fig
treatment
result
fip
remiss
experiment
fipv
infect
cat
ten
spf
cat
experiment
infect
fipv
show
clinic
sign
fip
challengeexposur
dash
line
time
develop
fever
lymphopenia
two
cat
becom
ill
dash
line
twoweek
treatment
cours
black
line
either
mgkg
group
mgkg
group
b
instig
within
day
diseas
onset
result
rapid
remiss
diseas
sign
grey
line
recurr
clinic
sign
four
six
week
two
treat
cat
group
group
b
necessit
second
cours
treatment
black
line
cat
remain
diseas
free
month
later
time
write
lymphopenia
less
equal
cellsul
blood
fig
rapidli
progress
depress
anorexia
hyperbilirubinemia
ascit
sever
lymphopenia
appear
proport
sever
overal
diseas
sign
one
cat
measur
nadir
lymphocytesul
blood
fig
rectal
temperatur
lymphocyt
level
remain
normal
two
asymptomat
cat
cat
develop
diseas
sign
divid
two
group
treat
either
mgkg
group
n
mgkg
group
b
n
sc
h
start
three
day
unequivoc
clinic
evid
fip
day
post
infect
fig
two
cat
develop
diseas
sign
serv
control
normal
blood
lymphocyt
count
rectal
temperatur
fig
virusassoci
fever
rapidli
normal
treatment
experiment
fipvinfect
cat
ten
spf
cat
experiment
infect
fipv
develop
hyperthermia
day
fipv
inocul
cat
two
cat
presum
resist
diseas
treat
fever
respond
rapidli
treatment
regardless
dosag
fig
virusassoci
lymphopenia
normal
treatment
experiment
fipvinfect
cat
eleven
spf
cat
experiment
infect
fipv
develop
lymphopenia
less
equal
cellsul
blood
within
day
fipv
inocul
cat
cat
one
two
cat
resist
infect
manifest
lymphopenia
second
resist
cat
mild
lymphopenia
lymphocyt
count
return
rapidli
prediseas
level
regardless
dosag
treat
cat
rapid
respons
treatment
lymphocyt
level
rectal
temperatur
return
preinfect
level
level
two
asymptomat
cat
fig
two
treat
cat
group
group
b
recurr
diseas
four
six
week
post
treatment
fig
two
cat
treat
second
time
two
week
respons
ident
primari
treatment
data
shown
ten
twice
treat
cat
remain
normal
date
eight
month
post
infect
signific
sign
toxic
note
primari
secondari
treatment
inject
caus
transient
sting
reaction
cat
within
compound
administr
local
transient
pain
evidenc
unusu
postur
lick
inject
site
andor
vocal
last
approxim
inject
inject
reaction
pronounc
anim
rel
other
reaction
inconsist
one
inject
next
decreas
time
biolog
activ
prodrug
fipv
infect
studi
progress
stage
initi
step
involv
screen
potenti
compound
identifi
one
favor
valu
done
vitro
use
crfk
cell
tissu
cultur
adapt
serotyp
ii
fipv
crfk
infect
experi
identifi
low
um
cytotox
highest
concentr
test
um
next
step
involv
ex
vivo
experi
use
natur
infect
periton
macrophag
cultur
establish
two
field
case
effus
fip
equal
effect
inhibit
wildtyp
serotyp
fipv
replic
natur
infect
periton
cell
inhibit
crfk
cell
therefor
anticip
would
also
effect
cat
infect
studi
virul
nontissu
cultur
adapt
serotyp
strain
second
stage
conduct
pk
studi
rule
acut
toxic
cat
treat
determin
optim
dosag
regimen
base
blood
tissu
distribut
acut
toxic
observ
laboratori
cat
singl
sc
iv
inject
subcutan
intraven
dosag
mgkg
result
similar
plasma
profil
intracellular
triphosph
level
approxim
um
felin
pbmc
h
period
occurr
neurolog
ocular
diseas
cat
fip
pedersen
cn
complic
earlier
trial
viral
proteas
inhibitor
pedersen
et
al
impetu
supplementari
pk
experi
test
abil
pass
bloodey
bloodbrain
barrier
singl
sc
dose
mgkg
result
intraocular
cn
drug
level
parent
near
effect
um
level
whether
amount
enter
eye
brain
cure
diseas
site
must
await
field
test
extrem
difficult
recreat
studi
ocular
neurolog
diseas
laboratori
clike
proteas
inhibitor
cross
bloodtobrain
barrier
csf
plasma
ratio
compar
kim
et
al
effect
preexist
neurolog
diseas
prevent
eventu
cn
involv
proport
treat
cat
pedersen
et
al
final
stage
laboratorybr
cat
experiment
infect
cattocat
passag
serotyp
strain
fipv
develop
sever
diseas
sign
five
ill
cat
treat
mgkg
dose
five
mgkg
given
subcutan
everi
h
dosag
mgkg
parent
drug
sustain
blood
level
h
pk
studi
time
higher
calcul
cell
cultur
experi
therefor
reason
postul
mgkg
would
also
effect
conserv
drug
reduc
potenti
toxic
treat
cat
manifest
rapid
revers
diseas
sign
start
within
h
compar
dosag
two
week
treatment
cat
well
back
normal
health
treatment
stop
although
uninfecteduntr
control
cat
use
studi
spontan
recoveri
extrem
uncommon
among
either
experiment
induc
pedersen
et
al
naturallyoccur
fip
ritz
et
al
fischer
et
al
result
cat
infect
studi
mirror
previou
experi
proteas
kim
et
al
two
treat
cat
one
dosag
group
experienc
diseas
relaps
four
six
week
treatment
end
second
twoweek
cours
result
rapid
resolut
diseas
sign
relaps
follow
proteas
inhibitor
treatment
pedersen
et
al
experiment
infect
de
grootmijn
et
al
observ
like
due
incomplet
clearanc
infect
andor
failur
mount
protect
immun
respons
infect
ten
treat
cat
remain
clinic
normal
date
eight
month
post
infect
system
sign
drug
toxic
note
cat
twoweek
twoweek
plu
second
twoweek
treatment
period
studi
tissu
cultur
cell
laboratori
cat
strongli
support
test
clientown
cat
variou
form
naturallyacquir
fip
earlier
studi
novel
clike
proteas
inhibitor
also
underw
type
pretest
pedersen
et
al
provid
templat
field
trial
field
test
demonstr
natur
occur
fipv
infect
difficult
treat
natur
infect
may
requir
somewhat
higher
dose
involv
mani
week
treatment
cure
rate
apt
lower
although
field
cat
treat
regain
outward
health
within
two
week
treatment
cat
remain
diseas
free
month
pedersen
et
al
nucleosid
analog
complet
inhibit
fipv
replic
crfk
cell
natur
infect
felin
periton
macrophag
vitro
concentr
um
detect
toxic
um
dosag
regimen
determin
pharmacokinet
studi
laboratori
cat
employ
success
treat
normal
fatal
experimentallyinduc
diseas
nucleosid
analog
hold
great
promis
treatment
natur
occur
fip
may
applic
studi
coronaviru
infect
speci
vitro
studi
dr
murphi
dr
pedersen
involv
use
cell
cultur
screen
compound
anticoronaviru
activ
lack
toxic
fund
grant
winn
felin
foundat
fund
followup
studi
involv
laboratori
cat
provid
center
companion
anim
health
gift
specifi
fip
research
numer
individu
donor
organ
sock
fip
davi
ca
foundat
philip
raskin
fund
kansa
citi
ks
perron
e
murakami
park
employe
gilead
scienc
inc
foster
citi
ca
usa
hold
stock
interest
compani
gilead
help
pk
metabol
analys
also
grate
maria
moreno
staff
uc
davi
care
cat
kirsten
murphi
manuscript
edit
drug
drugmetabolit
assay
kindli
provid
gilead
scienc
inc
foster
citi
ca
